ORIGINAL DATE: **02/21**

High Pointe House

SUBJECT: ADMINISTRATION OF BINAX.NOW TESTING AT THE HIGH POINTE HOUSE

PURPOSE: Rapid identification of infection with the SARS-CoV-2 virus in the hospice inpatient unit, the High Pointe House.

POLICY:
Supporting FDA emergency use authorization, patients at the hospice inpatient unit may be able to be tested via rapid antigen assay to allow for rapid identification of infection with the SARS-CoV-2 virus for individuals who are identified within seven days of symptom onset. Use of the rapid antigen test is allowed under MVH's CLIA waiver certificate.

PROCEDURE:

1. Patients are screened on a daily basis for signs and symptoms consistent with infection with the SARS-CoV-2 virus including fever greater than or equal to 100.4, cough, shortness of breath, loss of taste and/or smell, nausea/vomiting/diarrhea, congestion, headache.
2. New onset of any COVID compatible symptom noted above that is not attributable to expected disease progression or the active dying process may serve as an indication for rapid antigen testing for the SARS-CoV-2 virus within seven days of onset.
    a. Decision to pursue rapid antigen testing for the SARS-CoV-2 virus is made within the patient's clinical context.
3. An order from a physician or nurse practitioner is required for testing.
4. Clinician administering the test will don droplet precaution level PPE
    a. Insert the nasal swab into the nostril exhibiting the most drainage or congestion
    b. Using gentle rotation, push the swab until resistance is met
        - At the level of the nasal turbinates
        - Less than one inch into nostril
    c. Rotate the swab 5 times or more against the nasal wall
    d. Slowly remove the swab
    e. Using the same swab, repeat sample collection in the other nostril
    f. Add the reagent to the Binax.NOW test card
    g. Insert the sample nasal swab
    h. Close the Binax.NOW test card and WAIT 15 minutes

i. Read the results

- A negative specimen will give a single pink/purple colored control line in the top half of the window, indicating a negative result. This Control Line means that the detection part of the test was done correctly, but no COVID-19 antigen was detected.
- A positive specimen will give two pink/purple colored lines. This means that COVID-19 antigen was detected. Specimens with low levels of antigen may give a faint Sample Line. Any visible pink/purple line is positive.

j. Clinician administering and reading the test results will notify the patient (or HCP if invoked) and the High Pointe House provider of the test result.

5. CONTROL: every third rapid antigen COVID test will be confirmed with PCR testing assay for the SARS-Co-V-2 virus
6. EXCLUSIONS: As per the CDC and MA DPH guidance, individuals who have previously tested positive for the SARS-Co-V-2 virus within the past 90 days will not be retested for the SARS-Co-V-2 virus.

Responsibility: HPH staff
Distribution: Leadership

CEO Signature	_____	____/____/____ Date
CCIO Signature	Diane Farraher-Smith	2 /5 / 2021 Date
CMO Signature	_____	____/____/____ Date